Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12714MR)

This product GTTS-WQ12714MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12714MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3166MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ12644MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ14322MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ4242MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ1832MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ9556MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ15175MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ12539MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NV-01
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.